CA1161368A - Controlled protein fractionation - Google Patents
Controlled protein fractionationInfo
- Publication number
- CA1161368A CA1161368A CA000351044A CA351044A CA1161368A CA 1161368 A CA1161368 A CA 1161368A CA 000351044 A CA000351044 A CA 000351044A CA 351044 A CA351044 A CA 351044A CA 1161368 A CA1161368 A CA 1161368A
- Authority
- CA
- Canada
- Prior art keywords
- protein
- membrane
- solution
- plasma
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 106
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 106
- 238000005194 fractionation Methods 0.000 title claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 267
- 239000012510 hollow fiber Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000012528 membrane Substances 0.000 claims abstract description 40
- 239000002244 precipitate Substances 0.000 claims abstract description 26
- 239000000243 solution Substances 0.000 claims abstract description 25
- 238000005119 centrifugation Methods 0.000 claims abstract description 15
- 239000012460 protein solution Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 238000011026 diafiltration Methods 0.000 claims abstract description 6
- 239000010419 fine particle Substances 0.000 claims abstract description 4
- 210000002381 plasma Anatomy 0.000 claims description 109
- 239000006228 supernatant Substances 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 15
- 239000000835 fiber Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000005086 pumping Methods 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 18
- 238000012545 processing Methods 0.000 abstract description 5
- 230000007423 decrease Effects 0.000 abstract description 3
- 235000019441 ethanol Nutrition 0.000 description 133
- 238000007792 addition Methods 0.000 description 58
- 102000009027 Albumins Human genes 0.000 description 37
- 108010088751 Albumins Proteins 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 238000001816 cooling Methods 0.000 description 17
- 230000036425 denaturation Effects 0.000 description 13
- 238000004925 denaturation Methods 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 7
- 239000007974 sodium acetate buffer Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005187 foaming Methods 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 238000000665 Cohn process Methods 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000013494 PH determination Methods 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- -1 divinyl acrylonitrile Chemical compound 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000003134 recirculating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010058936 Cohn fraction V Proteins 0.000 description 1
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- 101710128029 Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000800755 Naja oxiana Alpha-elapitoxin-Nno2a Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000193803 Therea Species 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003297 denaturating effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001083 documented effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 101150115956 slc25a26 gene Proteins 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N vinyl-ethylene Natural products C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/10—Temperature control
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Water Supply & Treatment (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3603179A | 1979-05-04 | 1979-05-04 | |
| US36,031 | 1979-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1161368A true CA1161368A (en) | 1984-01-31 |
Family
ID=21886215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000351044A Expired CA1161368A (en) | 1979-05-04 | 1980-05-01 | Controlled protein fractionation |
Country Status (17)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100004496A1 (it) * | 2021-02-25 | 2022-08-25 | Univ Della Calabria | Recupero di farmaci biologici o loro frammenti da soluzioni impure mediante cristallizzazione o precipitazione con membrane |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2469193A (en) * | 1942-02-09 | 1949-05-03 | Research Corp | Protein fractionation |
| US2390074A (en) * | 1942-02-09 | 1945-12-04 | Research Corp | Protein product and process |
| US2770616A (en) * | 1951-01-29 | 1956-11-13 | Protein Foundation Inc | Fractionation of proteinaceous materials in blood plasma and liver tissue |
| GB1323681A (en) * | 1969-03-28 | 1973-07-18 | Nat Res Dev | Apparatus for use in the fractionation of solutions of protein aceous materials |
| US3869436A (en) * | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
| US3763135A (en) * | 1971-11-08 | 1973-10-02 | Baxter Laboratories Inc | Gamma globulin production from cohn fraction iii using polyethylene glycol |
| US4142966A (en) * | 1974-04-01 | 1979-03-06 | Monsanto Company | Membrane separation of water from aqueous mixtures |
| DE2444524A1 (de) * | 1974-09-18 | 1976-04-08 | Oeser Henning Dr | Verfahren und vorrichtung zur ausfaellung von human-blutplasma-bestandteilen |
| US3998946A (en) * | 1975-04-23 | 1976-12-21 | The Regents Of The University Of Minnesota | Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same |
| SE393535B (sv) * | 1975-09-11 | 1977-05-16 | Gambro Ab | Anordning for diffusion av emnen mellan tva fluider via semipermeabla membran |
| US4218312A (en) * | 1975-12-01 | 1980-08-19 | Monsanto Company | Membrane separation of organics from aqueous solutions |
| FR2380362A2 (fr) * | 1976-02-13 | 1978-09-08 | Baxter Travenol Lab | Faisceau de filaments creux, et procede et appareil d'enroulement de filaments creux |
| NL7711855A (nl) * | 1977-02-11 | 1978-08-15 | Baxter Travenol Lab | Werkwijze en inrichting voor het vervaardigen van filamentbundels en dergelijke bundels be- vattende dialysators. |
| DE2725757A1 (de) * | 1977-06-07 | 1978-12-21 | Fresenius Chem Pharm Ind | Vorrichtung zur fortlaufenden analyse niedermolekularer bestandteile in stroemenden fluessigkeiten |
| US4136094A (en) * | 1977-08-31 | 1979-01-23 | The Regents Of The University Of Minnesota | Preparation of intravenous human and animal gamma globulins and isolation of albumin |
-
1980
- 1980-04-29 GR GR61811A patent/GR68187B/el unknown
- 1980-04-30 FR FR8009775A patent/FR2455608A1/fr not_active Withdrawn
- 1980-05-01 WO PCT/US1980/000481 patent/WO1980002380A1/en not_active Application Discontinuation
- 1980-05-01 CA CA000351044A patent/CA1161368A/en not_active Expired
- 1980-05-01 JP JP50127480A patent/JPS56500442A/ja active Pending
- 1980-05-01 IL IL59975A patent/IL59975A/xx unknown
- 1980-05-02 BE BE6/47155A patent/BE883099A/fr not_active IP Right Cessation
- 1980-05-02 PT PT71179A patent/PT71179B/pt unknown
- 1980-05-02 AR AR280887A patent/AR224765A1/es active
- 1980-05-02 IT IT21790/80A patent/IT1131137B/it active
- 1980-05-02 ZA ZA00802667A patent/ZA802667B/xx unknown
- 1980-05-02 ES ES491138A patent/ES8107244A1/es not_active Expired
- 1980-05-02 NZ NZ193605A patent/NZ193605A/xx unknown
- 1980-05-05 FI FI801439A patent/FI801439A7/fi not_active Application Discontinuation
- 1980-11-17 EP EP19800901060 patent/EP0028246A4/en not_active Withdrawn
- 1980-12-17 DK DK537380A patent/DK537380A/da not_active Application Discontinuation
- 1980-12-29 NO NO803951A patent/NO803951L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK537380A (da) | 1980-12-17 |
| GR68187B (enrdf_load_stackoverflow) | 1981-11-09 |
| IL59975A0 (en) | 1980-07-31 |
| FI801439A7 (fi) | 1980-11-05 |
| EP0028246A1 (en) | 1981-05-13 |
| NZ193605A (en) | 1983-05-10 |
| ES491138A0 (es) | 1981-05-16 |
| EP0028246A4 (en) | 1982-03-29 |
| WO1980002380A1 (en) | 1980-11-13 |
| PT71179A (en) | 1980-07-01 |
| PT71179B (en) | 1982-06-20 |
| FR2455608A1 (fr) | 1980-11-28 |
| ES8107244A1 (es) | 1981-05-16 |
| NO803951L (no) | 1980-12-29 |
| IT8021790A0 (it) | 1980-05-02 |
| JPS56500442A (enrdf_load_stackoverflow) | 1981-04-09 |
| BE883099A (fr) | 1980-11-03 |
| IT1131137B (it) | 1986-06-18 |
| IL59975A (en) | 1983-07-31 |
| ZA802667B (en) | 1981-06-24 |
| AR224765A1 (es) | 1982-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0923308B1 (en) | Purification of biologically active peptides from milk | |
| JP3074401B2 (ja) | 血漿から繊維素原濃縮物を取出す方法およびその方法を実施する装置 | |
| Newman et al. | Methods for the production of clinically effective intermediate and high‐purity factor‐VIII concentrates | |
| US4272523A (en) | Fractionating citrate-stabilized plasma | |
| US3682881A (en) | Fractionation of plasma using glycine and polyethylene glycol | |
| WO1998001464A1 (en) | Methods for the selective separation of organic components from biological fluids | |
| AU2006287833B2 (en) | An ultra-high yield intravenous immune globulin preparation | |
| CA2621025A1 (en) | An ultra-high yield intravenous immune globulin preparation | |
| US5259971A (en) | Method of preparing fibrinogen | |
| CN104328101A (zh) | 一种凝血酶的制备方法 | |
| EP1087990A1 (en) | Method and apparatus for the production of purified plasma proteins | |
| US5252217A (en) | Blood coagulation factor XI concentrate having high specific activity, suitable for therapeutic use, and process for preparing same | |
| CN1546682A (zh) | 酶解与膜滤集成连续制取酪蛋白生物活性多肽的工艺 | |
| WO1993017776A9 (en) | Method of preparing fibrinogen | |
| CN108048434A (zh) | 一种蚯蚓中蚯蚓蛋白和蚓激酶的提取方法 | |
| JP2000506843A (ja) | セルロース系ろ過助剤を使用する血漿混合物のろ過 | |
| CA1161368A (en) | Controlled protein fractionation | |
| PT81012B (pt) | Processo para a recuperacao de hormonas de crescimento purificadas a partir de microrganismos tratados por engenharia genetica | |
| CN108660126A (zh) | 一种冻干人凝血酶的制备工艺 | |
| Wickerhauser et al. | Large scale preparation of macroglobulins | |
| US5770705A (en) | Method for recovering proteins from plasma using insoluble, water-absorbing material | |
| Bruning et al. | Prothrombal: a new concentrate of human prothrombin complex for clinical use | |
| CN109734796B (zh) | 一种从溶血血清中分离白蛋白的工艺 | |
| US4406886A (en) | Purification of antihemophilia factor VIII by precipitation with zinc ions | |
| US4486341A (en) | Fractionation of blood plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |